Overview


According to FutureWise analysis the market for Inotropic Agent in 2023 is US$ 2.12 billion, and is expected to reach US$ 5.11 billion by 2031 at a CAGR of 11.62%.

An inotrope can be an agent that alters muscular contractions. Negatively-inotropic agents reduce the force of muscle contractions. Positively inotropic drugs increase muscle contraction strength. The term inotropic state most often refers to drugs, which can affect the strength of heart muscle contraction. It can also refer to pathological circumstances. A large heart muscle can increase its inotropic status, while a small heart muscle could decrease it. There are both positive and negative inotropes that can be used for the management of different cardiovascular conditions. The specific pharmacological properties of each agent with respect to a condition are key factors in determining the best choice of agent. The inotropic state can be affected by the Calcium levels in the cytoplasm muscle cells. Negative inotropes tend to decrease this level. There are many factors that can affect calcium release. Because of the possibility of local tissue injury, it is best to give vasopressors through the main line. They are most likely safe when administered for less than two hours via good peripheral Intravenous catheterization. A positive inotropic agent can be used to increase intracellular calcium and/or stimulate the release of calcium from the sarcoplasmic reticulum. One of two types of calcium channels can be used to transport calcium into the cell: the long-lasting calcium channel or the transient calcium channel. These channels react to voltage changes differently. The L-type channels can be used to maintain an action pot while the T-type channels can be used to initiate them. L-type channels increase intracellular calcium via their action, which allows the action potential to be sustained longer and contractility can rise. For support of cardiac function in conditions such as decompensated congestive or septic heart failure, cardiogenic shock, cardiomyopathy, myocardial damage, and cardiogenic shock, positive inotropes can be used.
Inotropic agents can be used to treat low cardiac output conditions like cardiogenic shock, severe heart failure, and even cardiac surgery. These agents alter the contraction of the heart muscle. Inotropic drugs increase calcium release from the sarcoplasmic retina or increase calcium influx to the heart muscle cell. It is vital for the healthcare sector, and will likely rise in the forecast period. Market growth is possible due to an increase in inotropic medications delivered via these retail pharmacies. Because they are easy to access, patients prefer to purchase drugs from retail pharmacies. Anesthetists frequently use mild vasopressor or inotropic agents in large quantities to control the cardiovascular effects and general anesthesia. This indication is most commonly covered by phenylephrine (ephedrine), metaraminol, and phenylephrine (metaraminol). Inotropic agents, which are widely used in hemodynamic treatment, are often chosen with pre-determined goals. This includes a cardiac index, systemic or venous oxygen delivery, and/or vein saturation. This presents a great opportunity for market growth.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Inotropic Agent Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Inotropic Agent Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • GlaxosmithKline Plc
  • Sanofi
  • Eli Lilly and Company
  • Covis Pharma
  • Mylan N.V
  • Pfizer Inc
  • Hikma Pharmaceuticals PLC
  • Fresenius Kabi USA
  • Baxter
  • Sun pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Positive Inotropic Drugs
  • Negative Inotropic Drugs
  • Others

By Indication

  • Heart Attack
  • Heart Failure
  • Angina
  • Arrhythmia
  • Others

By Route of Administration

  • Oral
  • Prenteral
  • Others

By End User

  • Hospitals
  • Specialty Centers
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Inotropic Agent Market By Type, By Indication, By Route of Administration, By End User, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Inotropic Agent Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Inotropic Agent Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Inotropic Agent Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Inotropic Agent Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Positive Inotropic Drugs
        2. Negative Inotropic Drugs
        3. Others

  • 8.   Inotropic Agent Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Heart Attack
        2. Heart Failure
        3. Angina
        4. Arrhythmia
        5. Others

  • 9.   Inotropic Agent Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Prenteral
        3. Others

  • 10.   Inotropic Agent Market, By End Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Centers
        3. Others

  • 11.   Inotropic Agent Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Others

  • 12.   North America Inotropic Agent Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Inotropic Agent Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Inotropic Agent Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Inotropic Agent Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. GlaxosmithKline Plc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Sanofi
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Eli Lilly and Company
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Covis Pharma
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Mylan N.V
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Pfizer Inc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Hikma Pharmaceuticals PLC
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Fresenius Kabi USA
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Baxter
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Sun pharmaceuticals
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients